ESSA Pharma Inc. (EPIX)
Largest Insider Buys in Sector
EPIX Stock Price History Chart
EPIX Stock Performance
About ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, …
Insider Activity of ESSA Pharma Inc.
Over the last 12 months, insiders at ESSA Pharma Inc. have bought $0 and sold $12.83M worth of ESSA Pharma Inc. stock.
On average, over the past 5 years, insiders at ESSA Pharma Inc. have bought $4.85M and sold $6.85M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 9,223 shares for transaction amount of $21,213 was made by Parkinson David Ross (Chief Executive Officer) on 2023‑12‑14.
List of Insider Buy and Sell Transactions, ESSA Pharma Inc.
| 2024-11-01 | Sale | 10 percent owner | 7.88M 19.3487% | $1.53 | $12.02M | +23.21% | ||
| 2024-09-09 | Sale | Chief Operating Officer | 694 0.0016% | $6.00 | $4,164 | -39.24% | ||
| 2024-09-03 | Sale | Chief Operating Officer | 2,082 0.0048% | $6.03 | $12,554 | -10.12% | ||
| 2024-05-06 | Sale | Chief Operating Officer | 694 0.0016% | $6.95 | $4,823 | -22.71% | ||
| 2024-04-05 | Sale | Chief Operating Officer | 694 0.0015% | $7.94 | $5,510 | -31.98% | ||
| 2024-03-05 | Sale | Chief Operating Officer | 694 0.0015% | $8.98 | $6,232 | -34.62% | ||
| 2024-02-06 | Sale | Chief Operating Officer | 72,782 0.2007% | $10.29 | $748,927 | -42.65% | ||
| 2024-02-05 | Sale | Chief Operating Officer | 1,194 0.0031% | $9.58 | $11,440 | -39.56% | ||
| 2024-01-16 | Sale | Chief Operating Officer | 1,718 0.0043% | $10.01 | $17,197 | -33.41% | ||
| 2024-01-05 | Sale | Chief Operating Officer | 699 0.0015% | $6.11 | $4,271 | -0.93% | ||
| 2023-12-14 | Chief Executive Officer | 9,223 0.0081% | $2.30 | $21,213 | +4.17% | |||
| 2023-11-21 | director | 23,259 0.0523% | $5.73 | $133,274 | +7.40% | |||
| 2023-11-03 | director | 16,471 0.0373% | $5.99 | $98,661 | +3.83% | |||
| 2023-11-02 | director | 60,000 0.1371% | $5.35 | $321,000 | +16.45% | |||
| 2022-12-30 | Chief Executive Officer | 3,067 0.0072% | $2.60 | $7,974 | +17.06% | |||
| 2022-12-30 | Chief Financial Officer | 8,302 0.0194% | $2.60 | $21,585 | +17.06% | |||
| 2022-12-22 | Chief Executive Officer | 21,367 0.0493% | $2.39 | $51,067 | +25.11% | |||
| 2022-12-21 | Sale | director | 72,223 0.1656% | $2.41 | $174,401 | +23.01% | ||
| 2022-12-20 | Sale | director | 43,617 0.0986% | $2.53 | $110,351 | +15.75% | ||
| 2022-12-16 | Sale | director | 50,000 0.1156% | $2.67 | $133,500 | +12.21% |
Insider Historical Profitability
| BIOTECH GROWTH N V | 10 percent owner | 0 0% | $1.62 | 3 | 1 | <0.0001% |
| BB BIOTECH AG | 5879583 13.2516% | $1.62 | 2 | 1 | <0.0001% | |
| BERGER FRANKLIN M | director | 784404 1.7679% | $1.62 | 4 | 5 | <0.0001% |
| Parkinson David Ross | Chief Executive Officer | 65675 0.148% | $1.62 | 4 | 0 | +11.41% |
| Wood David S. | Chief Financial Officer | 33343 0.0751% | $1.62 | 1 | 0 | +17.06% |
Institutional Investor Ownership
| Bvf Inc Il | $74.28M | 19.72 | 8.75M | 0% | +$0 | 0.54 | |
| Bellevue Group | $66.98M | 17.78 | 7.89M | -0.11% | -$76,410.00 | 1.03 | |
| Morgan Stanley | $35.48M | 9.42 | 4.18M | -0.19% | -$68,174.70 | <0.01 | |
| Soleus Capital Management, L.P. | $30.48M | 8.09 | 3.59M | -17.05% | -$6.27M | 0.13 | |
| PFM Health Sciences | $25.3M | 6.72 | 2.98M | -8.65% | -$2.39M | 0.7 |